A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age

NCT03303625 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Viruses
Respiratory Tract Infections

Interventions

BIOLOGICAL: Ad26.RSV.preF (1*10^11 vp)
BIOLOGICAL: Ad26.RSV.preF (5*10^10 vp)
DRUG: Placebo

Sponsor

Janssen Vaccines & Prevention B.V.